PE20081723A1 - Vacuna contra el papilomavirus - Google Patents

Vacuna contra el papilomavirus

Info

Publication number
PE20081723A1
PE20081723A1 PE2008000212A PE2008000212A PE20081723A1 PE 20081723 A1 PE20081723 A1 PE 20081723A1 PE 2008000212 A PE2008000212 A PE 2008000212A PE 2008000212 A PE2008000212 A PE 2008000212A PE 20081723 A1 PE20081723 A1 PE 20081723A1
Authority
PE
Peru
Prior art keywords
hpv
polypeptide
vaccine against
against papillomavirus
residue
Prior art date
Application number
PE2008000212A
Other languages
English (en)
Inventor
Martine Baudin
Jean-Marc Balloul
Nathalie Silvestre
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of PE20081723A1 publication Critical patent/PE20081723A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SE REFIERE A UNA MOLECULA DE ACIDO NUCLEICO QUE CODIFICA AL MENOS UN POLIPEPTIDO E2 DEL PAPILOMAVIRUS. DICHO POLIPEPTIDO E2 SE ORIGINA A PARTIR DE PREFERENCIA VPH-16 QUE COMPRENDE LA SECUENCIA AMINOACIDICA QUE SE MUESTRA EN EL IDENTIFICADOR DE SECUENCIA Nº1, DONDE EL RESIDUO GLU EN LA POSICION 39 Y/O EL RESIDUO ILE EN LA POSICION 73 SE SUSTITUYEN POR UN RESIDUO ALA; ADEMAS CARECE DE REPLICACION O AL MENOS ACTIVACION DE TRANSCRIPCION. DICHA MOLECULA ES UTIL EN EL TRATAMIENTO DE UNA INFECCIONPERMANENTE CAUSADA POR AL MENOS VPH-AR
PE2008000212A 2007-01-30 2008-01-29 Vacuna contra el papilomavirus PE20081723A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07360004 2007-01-30
EP07360018 2007-05-15

Publications (1)

Publication Number Publication Date
PE20081723A1 true PE20081723A1 (es) 2008-12-14

Family

ID=39399907

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2008000212A PE20081723A1 (es) 2007-01-30 2008-01-29 Vacuna contra el papilomavirus

Country Status (20)

Country Link
US (1) US8420103B2 (es)
EP (2) EP2118292B1 (es)
JP (1) JP5474567B2 (es)
KR (1) KR101636575B1 (es)
CN (1) CN101617052A (es)
AR (1) AR065076A1 (es)
AT (1) ATE518958T1 (es)
AU (1) AU2008209759B2 (es)
BR (1) BRPI0806350A2 (es)
CA (1) CA2675355C (es)
CL (1) CL2008000249A1 (es)
DK (1) DK2118292T3 (es)
IL (2) IL199939A (es)
MX (1) MX2009008118A (es)
PE (1) PE20081723A1 (es)
PL (1) PL2118292T3 (es)
RU (2) RU2482189C2 (es)
TW (1) TW200840869A (es)
WO (1) WO2008092854A2 (es)
ZA (1) ZA200904932B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5474767B2 (ja) * 2007-05-15 2014-04-16 トランジェーヌ、ソシエテ、アノニム 多重遺伝子発現のためのベクター
TW200844230A (en) 2007-05-15 2008-11-16 Transgene Sa Signaling peptides
WO2014009433A1 (en) 2012-07-10 2014-01-16 Transgene Sa Mycobacterium resuscitation promoting factor for use as adjuvant
WO2015149051A1 (en) * 2014-03-28 2015-10-01 The Johns Hopkins University Treatment regimen using cancer vaccines and local adjuvants and their use
CN107075521B (zh) * 2014-11-04 2021-06-08 扬森疫苗与预防公司 治疗性hpv16疫苗
WO2017210649A1 (en) * 2016-06-03 2017-12-07 Etubics Corporation Compositions and methods for the treatment of human papillomavirus (hpv)-associated diseases
EP3518966A1 (en) * 2016-09-29 2019-08-07 GlaxoSmithKline Biologicals S.A. Compositions and methods of treatment of persistent hpv infection
CN111065406A (zh) 2017-06-21 2020-04-24 特兰斯吉恩股份有限公司 个性化疫苗
EP3461497A1 (en) 2017-09-27 2019-04-03 GlaxoSmithKline Biologicals S.A. Viral antigens
US11012555B2 (en) 2017-11-20 2021-05-18 International Business Machines Corporation Non-verbal sensitive data authentication
KR102222582B1 (ko) * 2018-02-02 2021-03-04 주식회사 에스엘백시젠 신규 다가 hpv 백신 조성물
JP2021516957A (ja) 2018-03-07 2021-07-15 トランジェーヌＴｒａｎｓｇｅｎｅ パラポックスウイルスベクター
CN116200416B (zh) * 2023-02-15 2024-03-12 北京康乐卫士生物技术股份有限公司 一种基于Tac启动子的质粒表达载体构建及其用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4711955A (en) 1981-04-17 1987-12-08 Yale University Modified nucleotides and methods of preparing and using same
US4769330A (en) 1981-12-24 1988-09-06 Health Research, Incorporated Modified vaccinia virus and methods for making and using the same
US4603112A (en) 1981-12-24 1986-07-29 Health Research, Incorporated Modified vaccinia virus
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
FR2643817B1 (fr) 1989-03-06 1993-12-17 Transgene Sa Composition pharmaceutique, utile a titre preventif ou curatif contre les tumeurs induites par les papillomavirus
DE3642912A1 (de) 1986-12-16 1988-06-30 Leybold Ag Messeinrichtung fuer paramagnetische messgeraete mit einer messkammer
FR2632863B2 (fr) 1987-10-29 1990-08-31 Transgene Sa Virus du fowlpox recombinant et vaccins derives de ces virus
US5100587A (en) 1989-11-13 1992-03-31 The United States Of America As Represented By The Department Of Energy Solid-state radioluminescent zeolite-containing composition and light sources
US5756102A (en) 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
KR100242671B1 (ko) 1991-03-07 2000-03-02 고돈 에릭 유전학적으로 처리한 백신 균주
GB9105383D0 (en) * 1991-03-14 1991-05-01 Immunology Ltd An immunotherapeutic for cervical cancer
US5179993A (en) 1991-03-26 1993-01-19 Hughes Aircraft Company Method of fabricating anisometric metal needles and birefringent suspension thereof in dielectric fluid
DE4123760C2 (de) 1991-07-18 2000-01-20 Dade Behring Marburg Gmbh Seroreaktive Bereiche auf den HPV 16 Proteinen E1 und E2
US6013638A (en) 1991-10-02 2000-01-11 The United States Of America As Represented By The Department Of Health And Human Services Adenovirus comprising deletions on the E1A, E1B and E3 regions for transfer of genes to the lung
GB9223084D0 (en) 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5674703A (en) * 1992-12-02 1997-10-07 Woo; Savio L. C. Episomal vector systems and related methods
FR2705686B1 (fr) 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6133028A (en) 1993-05-28 2000-10-17 Transgene S.A. Defective adenoviruses and corresponding complementation lines
US5698443A (en) 1995-06-27 1997-12-16 Calydon, Inc. Tissue specific viral vectors
MXPA96005662A (es) * 1994-05-16 2004-08-19 Merck & Co Inc Vacunas de papilomavirus.
US5525711A (en) 1994-05-18 1996-06-11 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Pteridine nucleotide analogs as fluorescent DNA probes
US6638762B1 (en) 1994-11-28 2003-10-28 Genetic Therapy, Inc. Tissue-vectors specific replication and gene expression
US5998205A (en) 1994-11-28 1999-12-07 Genetic Therapy, Inc. Vectors for tissue-specific replication
FR2727689A1 (fr) 1994-12-01 1996-06-07 Transgene Sa Nouveau procede de preparation d'un vecteur viral
US5837520A (en) 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors
FR2749323B1 (fr) * 1996-06-04 1998-07-10 Pasteur Merieux Serums Vacc Pseudo-particules virales utiles en tant que vecteur de delivrance d'acide nucleique
IL127692A0 (en) 1996-07-01 1999-10-28 Rhone Poulenc Rorer Sa Method for producing recombinant adenovirus
KR100503701B1 (ko) 1996-11-20 2005-07-26 인트로겐 테라페티스, 인코퍼레이티드 아데노바이러스 벡터를 생산하고 정제하는 개선된 방법
ATE477320T1 (de) 1996-12-13 2010-08-15 Schering Corp Methoden zur virus-reinigung
WO1998056415A1 (en) 1997-06-11 1998-12-17 Aquila Biopharmaceuticals, Inc. Purified saponins as oral adjuvants
FR2766091A1 (fr) 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
WO1999014377A2 (en) 1997-09-16 1999-03-25 Innogenetics N.V. Detection and identification of human papillomavirus by pcr and type-specific reverse hybridization
WO2000046355A2 (en) 1999-02-04 2000-08-10 Geron Corporation Telomerase reverse transcriptase transcriptional regulatory sequences
FR2774699B1 (fr) * 1997-11-17 2003-10-03 Rhone Poulenc Rorer Sa Methode de reduction des evenements de recombinaison homologue
FR2777570A1 (fr) 1998-04-17 1999-10-22 Transgene Sa Mutant ayant une activite phosphoribosyl transferase
JP3864610B2 (ja) 1998-05-21 2007-01-10 旭硝子株式会社 水分散型撥水撥油剤組成物およびその製造方法
US6900049B2 (en) 1998-09-10 2005-05-31 Cell Genesys, Inc. Adenovirus vectors containing cell status-specific response elements and methods of use thereof
US20020037274A1 (en) 1998-10-26 2002-03-28 Angelica Williams Single agent method for killing tumor and tumor associated endothelial cells using adenoviral mutants
US6582693B2 (en) * 1998-11-30 2003-06-24 Lemery, S.A. De C.V. Recombinant MVA virus expressing the E2 gene of Bovine papillomavirus and its use in the therapy of tumors generated by papillomaviruses
FR2787465A1 (fr) 1998-12-21 2000-06-23 Transgene Sa Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
CZ20012428A3 (cs) 1998-12-31 2001-11-14 Aventis Pharma S. A. Způsob separace virových částic
DE60029195T2 (de) 1999-02-22 2007-06-28 Transgene S.A. Verfahren zur Gewinnung von purifizierter Virenzusammensetzung
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
WO2001014416A2 (en) 1999-08-25 2001-03-01 Merck & Co., Inc. Synthetic papillomavirus genes optimized for expression in human cells
EP1230378B1 (en) 1999-11-15 2007-06-06 Onyx Pharmaceuticals, Inc. An oncolytic adenovirus
CA2341356C (en) 2000-04-14 2011-10-11 Transgene S.A. Poxvirus with targeted infection specificity
US20020029498A1 (en) 2000-07-03 2002-03-14 Howard Harrison Rapid cool iron and related iron improvements
WO2002008435A1 (en) 2000-07-21 2002-01-31 Glaxo Group Limited Codon-optimized papilloma virus sequences
JP4080423B2 (ja) 2001-05-30 2008-04-23 トランジェーヌ、ソシエテ、アノニム アデノウイルスタンパク質ｉｘ、ならびにキャプシドアセンブリー、転写活性および核再組織化に関与するそのドメイン
CA2457890A1 (en) 2001-08-23 2003-03-06 Merck & Co., Inc. Vaccine using papillomavirus e proteins delivered by viral vector
JP4895505B2 (ja) * 2002-05-16 2012-03-14 バヴァリアン・ノルディック・アクティーゼルスカブ 変異ワクシニアウイルスアンカラ（ｍｖａ）ゲノム中の挿入部位としての遺伝子間領域
GB0222953D0 (en) * 2002-10-03 2002-11-13 Glaxo Group Ltd Novel Compounds
US20090028874A1 (en) * 2003-12-24 2009-01-29 Leiden University Medical Center Synthetic Protein as Tumor-Specific Vaccine
US20070014810A1 (en) 2003-12-31 2007-01-18 Denise Baker Inducing cellular immune responses to human papillomavirus using peptide and nucleic acid compositions

Also Published As

Publication number Publication date
JP5474567B2 (ja) 2014-04-16
US20100143408A1 (en) 2010-06-10
RU2013102035A (ru) 2014-07-27
IL215599A (en) 2014-11-30
CN101617052A (zh) 2009-12-30
CA2675355A1 (en) 2008-08-07
ZA200904932B (en) 2010-04-28
CL2008000249A1 (es) 2008-05-30
AU2008209759A1 (en) 2008-08-07
EP2118292A2 (en) 2009-11-18
US8420103B2 (en) 2013-04-16
WO2008092854A3 (en) 2008-10-30
RU2009130791A (ru) 2011-03-10
EP2390340A2 (en) 2011-11-30
EP2390340A3 (en) 2012-02-22
PL2118292T3 (pl) 2011-12-30
MX2009008118A (es) 2009-10-13
DK2118292T3 (da) 2011-10-24
CA2675355C (en) 2015-04-28
IL199939A (en) 2013-02-28
KR20090129399A (ko) 2009-12-16
AR065076A1 (es) 2009-05-13
JP2010516287A (ja) 2010-05-20
BRPI0806350A2 (pt) 2011-09-06
IL215599A0 (en) 2011-11-30
IL199939A0 (en) 2010-04-15
KR101636575B1 (ko) 2016-07-05
AU2008209759B2 (en) 2013-03-21
TW200840869A (en) 2008-10-16
WO2008092854A2 (en) 2008-08-07
RU2482189C2 (ru) 2013-05-20
EP2118292B1 (en) 2011-08-03
ATE518958T1 (de) 2011-08-15

Similar Documents

Publication Publication Date Title
PE20081723A1 (es) Vacuna contra el papilomavirus
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
ES2586418T3 (es) Vacuna de proteína de fusión
CY1121632T1 (el) Η rv2386c πρωτεϊνη φυματιωσης, συνθεσεις και χρησεις αυτης
EP3552622A3 (en) Priming of an immune response
PE20120817A1 (es) Peptidos tau antigenicos y usos de los mismos
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
ES2688623T3 (es) Proteínas de fusión que se unen a factores de crecimiento
RS53455B (en) OPTIONS DERIVED FROM ActRIIB AND THEIR USE
EA201270517A1 (ru) Микобактериальные вакцины
MX346862B (es) Secuencias consenso de envoltura de vih y método para usar las mismas.
ES2539280T3 (es) Procedimiento de reducción de la expresión génica mediante el uso de codones modificado
UA94717C2 (ru) Модифицированный вирус гриппа, предназначенный для мониторинга и повышения эффективности вакцины
WO2009026465A3 (en) Composition and methods of making and using influenza proteins
EP2442483A3 (en) Elliptic curve Pinstov Vanstone signature scheme with authenticated message recovery
ES2454773T3 (es) Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN
UA107330C2 (uk) Туберкульозний білок rv3616c та його застосування
ES2531115T3 (es) Combinaciones de clados de RrgB neumocócicos
ATE473238T1 (de) Tuberkulose vaccine mit verbesserter effizienz
PE20110394A1 (es) Virus sincitial respiratorio vivo atenuado
NZ702146A (en) Peptides derived from viral proteins for use as immunogens and dosage reactants
WO2008151633A3 (en) Vectors for vaccines against lentivirus infections
PE20110106A1 (es) Peptidos mediadores del eflujo del colesterol mejorados
WO2007082734A3 (en) Influenza vaccine
NZ603854A (en) West nile virus vaccine

Legal Events

Date Code Title Description
FD Application declared void or lapsed